Analysis of dal-OUTCOMES included 15,817 patients ( 97 % statin-treated ) randomly assigned 4 to 12 weeks after ACS to treatment with dalcetrapib ( a cholesteryl ester transfer protein inhibitor ) or placebo and followed for a median 31 months .